Lv78
3840 积分 2024-05-26 加入
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial
1个月前
已完结
Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome
2个月前
已完结
LB1256 TRIV-509, a dual inhibitor of KLK5 and KLK7, rapidly improves barrier integrity and markers of epidermal differentiation in atopic dermatitis skin explants
2个月前
已完结
Unleashing the therapeutic potential of human kallikrein-related serine proteases
2个月前
已完结
Clinical pathway for the diagnosis and treatment of moderate to severe atopic dermatitis in China （2023）: an expert consensus
2个月前
已完结
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies
3个月前
已完结
Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials
3个月前
已完结
Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn's disease: a phase 2a induction trial
3个月前
已完结
Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn's disease: a phase 2a induction trial
3个月前
已完结
Risankizumab for Ulcerative Colitis
3个月前
已完结
皖公网安备34019202002308
